EGFR and non-small cell lung carcinoma: The ADJUVANT-CTONG 1104 trial (Clinicaltrials.gov NCT01405079) demonstrated that the first-generation EGFR-TKI adjuvant gefitinib improves disease-free survival (DFS) from 19.8 months to 30.8 months for resected EGFR mutant NSCLC with N1/N2 metastasis; the subsequent ADAURA trial, the first international study with the third-generation EGFR-TKI osimertinib, reported positive outcomes for adjuvant TKIs in patients with EGFR mutations as well (7–10).